Calcium Electroporation for Treatment of Cutaneous Metastases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01941901|
Recruitment Status : Recruiting
First Posted : September 13, 2013
Last Update Posted : August 31, 2015
|Condition or disease||Intervention/treatment||Phase|
|Cutaneous Metastases||Drug: Calcium electroporation Drug: Electrochemotherapy with bleomycin||Phase 2|
Double-blinded phase II clinical study. We will compare the effect of calcium electroporation for the treatment of cutaneous metastases with standard treatment: electrochemotherapy with intratumoral injection of bleomycin. Separate randomisation will be performed and the lesions will be treated with either intratumoral injection of calcium or bleomycin. It is a once only treatment and the patients will be followed up for 6 months.
It is a non-inferiority study and we accept a difference in response on 15%.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Calcium Electroporation for Treatment of Cutaneous Metastases|
|Study Start Date :||September 2013|
|Estimated Primary Completion Date :||April 2018|
|Estimated Study Completion Date :||April 2018|
Experimental: Calcium electroporation
The metastases will be treated with intratumoral injection of calcium chlorid followed by electrotransfer.
It is a once-only treatment. Calcium chlorid concentration: 9mg/ml. Total dose: 0,5ml/cm3 tumor volume.
Drug: Calcium electroporation
Intratumoral injection, once only treatment.
Active Comparator: Electrochemotherapy with bleomycin
The metastases will be treated with intratumoral injection of bleomycin followed by electrotransfer.
It is a once only treatment. bleomycin concentration: 1000 IU/ml. Total dose: o,5 ml/cm3 tumor volume.
Drug: Electrochemotherapy with bleomycin
Intratumoral injection, once only treatment
- Tumor response [ Time Frame: After 6 months ]Response evaluated by "Response Evaluation Criteria in Solid Tumors" (RECIST) guidelines version 1.1.
- Adverse events to calcium electroporation [ Time Frame: After 6 months ]Describe adverse events using Common Terminology for Adverse Events, version 4.0
- Compare tumor response of calcium electroporation with tumor response of electroporation. Response is evaluated by RECIST criteria. [ Time Frame: After 6 months ]It is a non-inferiority study, and we accept a difference in response on 15%.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01941901
|Contact: Julie Gehlfirstname.lastname@example.org|
|Department of Oncology, Copenhagen University Hospital, Herlev||Recruiting|
|Herlev, Denmark, 2730|
|Contact: Julie Gehl 004538683868 email@example.com|
|Principal Investigator: Julie Gehl|
|Principal Investigator:||Julie Gehl||Department of Oncology, Copenhagen University hospital, Herlev|